Treatment of Chemotherapy-Associated Side Effects
Which of the following acute chemotherapy-induced emesis (CIE) prevention medications do you generally recommend for the following chemotherapy regimens?
Which of the following acute chemotherapy-induced emesis (CIE) prevention medications do you generally recommend for the following chemotherapy regimens?
How would you compare docetaxel/ cyclophosphamide (TC) to AC in terms of safety and tolerability?
In my practice, when aprepitant is used in combination with a 5-HT3 receptor antagonist and dexamethasone, I use a lower dose of dexamethasone compared to that used with a 5-HT3 receptor antagonist and dexamethasone alone.
A patient with metastatic cancer receives paclitaxel qwk and has not shown any signs of hypersensitivity on a premedication regimen of dexamethasone/ diphenhydramine/ famotidine. Treatment will be administered indefinitely if stable or responding.
A 60-year-old man with metastatic carcinoma of unknown primary is receiving his second cycle of paclitaxel/carboplatin with standard paclitaxel premedication. He experienced a clinical response after the first cycle. Ten minutes into the second paclitaxel infusion, he develops chest tightness and shortness of breath. The paclitaxel infusion is stopped, and methylprednisolone/ diphenhydramine is administered. After 45 minutes, the patient’s symptoms have abated, although he is still anxious.
If you use
nab
paclitaxel, generally how often do you use steroids as part of your routine premedication regimen? (n = 81)
How would you compare the safety/tolerability of
nab
paclitaxel to paclitaxel?
Approximately what percent of the patients in your practice who receive adjuvant chemotherapy develop the following conditions? (Median)
Approximately what percent of your patients receiving each of the following therapies experience chemotherapy-related neuropathy? (Mean)
Which of the following is your most common approach to chemotherapy-related neuropathy in the curative setting?
Which of the following is your most common approach to chemotherapy-related neuropathy in the curative setting?
Which of the following is your most common approach to chemotherapy-related neuropathy in the curative setting?
Which of the following is your most common approach to chemotherapy-related neuropathy in the curative setting?
A 58-year-old diabetic is on her sixth of 12 planned cycles of modified FOLFOX with bevacizumab for first-line treatment of Stage IV colon cancer. She is responding to treatment but has developed painful persistent tingling in fingers and toes but no interference with activities of daily life.
Chemotherapy-free intervals are a reasonable option when administering FOLFOX for metastatic colon cancer.
